To more accurately assess the impact of MYC amp on OS, we excluded 13 cases that would be expected to have poor outcomes: MYC amp at lymphoma relapse (N = 5), non-DLBCL morphology (N = 5; 3 HGBCL; 2 plasmablastic lymphomas) and transformation from CLL or FL with prior anthracycline use (N = 3) (Supplementary data). This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.